Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP4 | P49662 | 1/20 | 0.34 |
| ▸ | CASP5 | P51878 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27097437 | 1.00 | ACHE (0.62) | ACHECHRM5ADRA2CSMN1; SMN2MAPT | |
| SCHEMBL27097444 | 0.88 | ACHE (0.49) | ACHECHRM5ADRA2CSMN1; SMN2MAPT | |
| SCHEMBL27097569 | 0.88 | ACHE (0.49) | ACHECHRM5ADRA2CSMN1; SMN2MAPT | |
| SCHEMBL20663187 | 0.88 | CHRM5 (0.58) | ACHECHRM5ADRA2CSMN1; SMN2MAPT | |
| SCHEMBL19264112 | 0.85 | ACHE (0.50) | ACHECHRM5ADRA2CHRH3 | |
| SCHEMBL12403174 | 0.85 | ACHE (0.50) | ACHECHRM5ADRA2CHRH3 | |
| SCHEMBL27097435 | 0.85 | ACHE (0.46) | ACHECHRM5ADRA2CHRH3 | |
| SCHEMBL27097594 | 0.85 | ACHE (0.63) | ACHECHRM5ADRA2CSMN1; SMN2OPRM1 | |
| SCHEMBL27097436 | 0.85 | ACHE (0.63) | ACHECHRM5ADRA2CSMN1; SMN2OPRM1 | |
| SCHEMBL15251335 | 0.82 | CHRM5 (0.56) | ACHECHRM5ADRA2CSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | ACHE 3025/4885CHRM5 4367/4885ADRA2C 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.